Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Akero Therapeutics Inc.

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Announces Proposed Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.